BioCentury
ARTICLE | Top Story

NICE eyes alternative payment models for cell therapies

March 30, 2016 1:31 AM UTC

An expert advisory group created by the U.K.'s NICE found that the committee's appraisal methods and decision framework are applicable to regenerative medicines and cell therapies, and recommended that NICE develop alternative payment methods such as a lifetime leasing model to manage and share the therapies' financial risk. The details came in a report NICE issued on Tuesday.

At the request of the NHS's Regenerative Medicine Expert Group, NICE launched a mock technology appraisal in April 2015 to evaluate the suitability of its existing methods for cell therapies and formed an expert panel to conduct the study. To evaluate NICE's methodologies, the panel chose a hypothetical chimeric antigen receptor (CAR) T cell therapy against CD19 to treat relapsed or refractory B cell acute lymphoblastic leukemia (ALL), and considered two different product profiles -- the cell therapy as a curative treatment, or as a bridging therapy in preparation for a hematopoietic stem cell transplant (HSCT). ...